SCHEMBL2499683

SCHEMBL2499683

Cc1c(C(=O)O)ccc(C=O)c1C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.40
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.34
NOTUM Q6P988 3/20 0.33
NSD2 O96028 1/20 0.33
PKM P14618 1/20 0.33
APEX1 P27695 1/20 0.33
CASP3 P42574 1/20 0.33
RECQL P46063 1/20 0.33
CASP6 P55212 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
GPR35 Q9HC97 2/20 0.33
KDM5A P29375 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2502722 0.80 MAPT (0.42) POLBALDH1A1MAPTHPGDKDM4E
SCHEMBL12760674 0.77 ALDH1A1 (0.46) POLBALDH1A1L3MBTL1TDP1HPGD
SCHEMBL2498153 0.74 MAPT (0.38) POLBMAPTNOTUMGPR35CYP1A2
SCHEMBL17599653 0.74 ALDH1A1 (0.44) POLBALDH1A1L3MBTL1TDP1MAPT
SCHEMBL16762134 0.73 TAS2R14 (0.40) ALDH1A1MAPTHPGDKDM4ENOTUM
SCHEMBL2505142 0.73 MAPT (0.37) POLBMAPTNOTUMGPR35CYP1A2
SCHEMBL2499752 0.73 GRM1 (0.39) POLBALDH1A1MAPTKDM4ENOTUM
SCHEMBL20594317 0.73 GABRP (0.46) POLBALDH1A1L3MBTL1TDP1MAPT
SCHEMBL7080684 0.72 CYP1A2 (0.48) POLBALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL8384594 0.70 POLB (0.41) POLBALDH1A1L3MBTL1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 POLB 4662/4885ALDH1A1 1939/4885L3MBTL1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.